Abstract：【Objective】To analyze the efficacy of erlotinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) who failed first-line standard chemotherapy regimen. 【Methods】A total of 90 patients with advanced NSCLC were divided into two groups according to the order of admission. Group A was treated with oral erlotinib 150mg/d and group B was treated with pemetrexed 500mg/m2 intravenously. The clinical effects of the two groups were analyzed. 【Results】The total effective rate and disease control rate between the two groups were not significantly different (P>0.05). There were no significant differences in the levels of carbohydrate antigen 50 (CA50) and cytokeratin 19 fragment (CYFRA21-1) between the two groups before treatment (P>0.05). After treatment, the levels of CA50 andCYFRA21-1 in each group were lower than those before treatment (P<0.05). However, there were no significant differences between the two groups after treatment (P>0.05). The overall quality of life in group A was better than that in group B (P<0.05). The main adverse reactions in group A were rash and diarrhea, while in group B, bone marrow suppression and gastrointestinal reaction were the main side effects. There was significant difference in the incidence of adverse reactions between the two groups (P<0.05). 【Conclusion】The efficacy of erlotinib and pemetrexide in the treatment of advanced NSCLC with failure of the first-line standard chemotherapy regimen is similar. They both can reduce the levels of tumor markers. Erlotinib has obvious advantage in improving the quality of life.
何志惠, 卢彦达, 黄芬, 雷俊华, 曾江正. 厄洛替尼与培美曲塞用于一线标准化疗方案失败的晚期NSCLC的疗效[J]. 医学临床研究, 2019, 36(8): 1472-1474.
HE Zhi-hui, LU Yan-da, HUANG Fen,et al. Effect of Erlotinib and Pemetrexed on Late Stage of NSCLC Patients with Failure of First-line Standard Chemotherapy. JOURNAL OF CLINICAL RESEARCH, 2019, 36(8): 1472-1474.
2019, Vol. 36 
